<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0701256532
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ALEVIO 25MG F.C.TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        TOPIRAMATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        25
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        25.30
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Jamjoom Pharmaceuticals Factory Company" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory Company
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 394]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            JAMJOOM PHARMACEUTICALS CO. LTD.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory  Company
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N03AX11 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Alevio&trade; belongs to a group of medicines called<br />&ldquo;antiepileptic medicines.&rdquo; It is used:<br />- alone to treat seizures in adults and children over<br />age 6<br />- with other medicines to treat seizures in adults and<br />children aged 2 years and above<br />- to prevent migraine headaches in adults</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take Alevio&trade;</p><p>- if you are allergic to topiramate or any of the other<br />ingredients of this medicine (listed in section 6).<br />- for migraine prevention: if you are pregnant or if<br />you are a woman of childbearing potential unless you<br />are using effective contraception (see section<br />&lsquo;pregnancy and breast-feeding&rsquo; for further<br />information). You should talk to your doctor about<br />the best kind of contraception to use while you are<br />taking Alevio&trade;.<br />If you are not sure if the above applies to you, talk to<br />your doctor or pharmacist before using Alevio&trade;.<br />Warnings and precautions<br />Talk to your doctor or pharmacist before taking<br />Alevio&trade; if you:<br />- have kidney problems, especially kidney stones, or<br />are getting kidney dialysis<br />- have a history of blood and body fluid abnormality<br />(metabolic acidosis)<br />- have liver problems<br />- have eye problems, especially glaucoma<br />- have a growth problem<br />- are on a high fat diet (ketogenic diet)<br />- are taking Alevio&trade; to treat epilepsy and you are<br />pregnant or a woman of childbearing potential (see<br />section &lsquo;pregnancy and breast-feeding&rsquo; for further<br />information)<br />If you are not sure if any of the above applies to you,<br />talk to your doctor or pharmacist before using<br />Alevio&trade;.<br />It is important that you do not stop taking your<br />medicine without first consulting your doctor.<br />You should also talk to your doctor before taking any<br />medicine containing topiramate that is given to you as<br />an alternative to Alevio&trade;.<br />You may lose weight if you use Alevio&trade; so your<br />weight should be checked regularly when using this<br />medicine. If you are losing too much weight or a<br />child using this medicine is not gaining enough<br />weight, you should consult your doctor.<br />A small number of people being treated with<br />antiepileptic medicines such as Alevio&trade; have had<br />thoughts of harming or killing themselves. If at any<br />time you have these thoughts, immediately contact<br />your doctor.<br />Alevio&trade; may in rare cases cause high levels of<br />ammonia in the blood (seen in blood tests) which can<br />lead to a change in brain function, especially if you<br />are also taking a medicine called valproic acid or<br />sodium valproate. Since this may be a severe<br />condition, tell your doctor immediately if the<br />following symptoms occur (see also section 4<br />&lsquo;Possible side effects&rsquo;):<br />- difficulty thinking, remembering information, or<br />solving problems<br />- being less alert or aware<br />- feeling very sleepy with low energy<br />At higher doses of Alevio&trade;, the risk of developing<br />these symptoms may increase.<br />Other medicines and Alevio&trade;<br />Tell your doctor or pharmacist if you are taking, have<br />recently taken or might take any other medicines.<br />Alevio&trade; and certain other medicines can affect each<br />other. Sometimes the dose of some of your other<br />medicines or Alevio&trade; will have to be adjusted.<br />Especially, tell your doctor or pharmacist if you are<br />taking:<br />- other medicines that impair or decrease your<br />thinking, concentration, or muscle coordination (e.g.<br />central nervous system depressant medicines such as<br />muscle relaxants and sedatives).<br />- birth control pills. Alevio&trade; may make your birth<br />control pills less effective. You should talk to your<br />doctor about the best kind of contraception to use<br />while you are taking Alevio&trade;.<br />Tell your doctor if your menstrual bleeding changes<br />while you are taking birth control pills and Alevio&trade;.<br />Keep a list of all the medicines you take. Show this<br />list to your doctor and pharmacist before you start a<br />new medicine.<br />Other medicines you should discuss with your doctor<br />or pharmacist include other anti-epileptic medicines,<br />risperidone, lithium, hydrochlorothiazide, metformin,<br />pioglitazone, glyburide, amitriptyline, propranolol,<br />diltiazem, venlafaxine, flunarazine, St. John&#39;s wort<br />(Hypericum perforatum) (a herbal preparation used to<br />treat depression).<br />If you are not sure if any of the above applies to you,<br />talk to your doctor or pharmacist before using<br />Alevio&trade;.<br />Alevio&trade; with food and drink<br />You can take Alevio&trade; with or without food. Drink<br />plenty of fluids during the day to prevent kidney<br />stones while taking Alevio&trade;. You should avoid<br />drinking alcohol when taking Alevio&trade;.<br />Pregnancy and breast-feeding<br />If you are pregnant or breast-feeding, think you may<br />be pregnant or are planning to have a baby, ask your<br />doctor for advice before taking this medicine.<br />Your doctor will discuss use of contraceptives with<br />you, as well as discussing whether Alevio&trade; is suitable<br />for you. As with other anti-epileptic medicines, there<br />is a risk of harm to the unborn child if Alevio&trade; is<br />used during pregnancy. Make sure you are very clear<br />about the risks and the benefits of using Alevio&trade; for<br />epilepsy during pregnancy.<br />You should not take Alevio&trade; for migraine prevention<br />if you are pregnant or you are able to become<br />pregnant and you are not using effective<br />contraception.<br />Mothers who breast-feed while taking Alevio&trade; must<br />tell the doctor as soon as possible if the baby<br />experiences anything unusual.<br />Driving and using machines<br />Dizziness, tiredness, and vision problems may occur<br />during treatment with Alevio&trade;. Do not drive or use<br />any tools or machines without talking to your doctor<br />first.<br />Alevio&trade; contains lactose<br />If you have been told by your doctor that you have an<br />intolerance to some sugars, contact&nbsp;your doctor<br />before taking this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has<br />told you. Check with your doctor or pharmacist if you<br />are not sure.<br />- Your doctor will usually start you on a low dose of<br />Alevio&trade; and slowly increase your dose until the best<br />dose is found for you.<br />- Alevio&trade; tablets are to be swallowed whole. Avoid<br />chewing the tablets as they may leave a bitter taste.<br />- Alevio&trade; can be taken before, during, or after a<br />meal. Drink plenty of fluids during the day to prevent<br />kidney stones while taking Alevio&trade;.<br />If you take more Alevio&trade; than you should<br />- See a doctor right away. Take the medicine pack<br />with you.<br />- You may feel sleepy, tired, or less alert; lack<br />coordination; have difficulty speaking or<br />concentrating; have double or blurred vision; feel<br />dizzy due to low blood pressure; feel depressed or<br />agitated; or have abdominal pain, or seizures (fits).<br />Overdose can happen if you are taking other<br />medicines together with Alevio&trade;.<br />If you forget to take Alevio&trade;<br />- If you forget to take a dose, take it as soon as you<br />remember it. However, if it is almost time for your<br />next dose, skip the missed dose and continue as usual.<br />If you miss two or more doses, contact your doctor.<br />- Do not take a double dose (two doses at the same<br />time) to make up for a forgotten dose.<br />If you stop taking Alevio&trade;<br />Do not stop taking this medicine unless told to do so<br />by your doctor. Your symptoms may return. If your<br />doctor decides to stop this medication, your dose may<br />be decreased gradually over a few days.<br />If you have any further questions on the use of this<br />product, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side<br />effects, although not everybody gets them.<br />Tell your doctor, or seek medical attention<br />immediately if you have the following side effects:<br />Very common (may affect more than 1 in 10<br />people)<br />- Depression (new or worse)<br />Common (may affect up to 1 in 10 people)<br />- Seizures (fits)<br />- Anxiety, irritability, changes in mood, confusion,<br />disorientation<br />- Problems with concentration, slowness of thinking,<br />loss of memory, problems with memory (new onset,<br />sudden change or increased severity)<br />- Kidney stone, frequent or painful urination<br />Uncommon (may affect up to 1 in 100 people)<br />- Increased acid level in the blood (may cause<br />troubled breathing including shortness of breath, loss<br />of appetite, nausea, vomiting, excessive tiredness, and<br />fast or uneven heart beats)<br />- Decreased or loss of sweating (particularly in young<br />children who are exposed to high temperatures)<br />- Having thoughts of serious self-harm, trying to<br />cause serious self-harm<br />- Loss of part of the field of vision<br />Rare (may affect up to 1 in 1,000 people)<br />- Glaucoma &ndash; blockage of fluid in eye causing<br />increased pressure in the eye, pain, or decreased<br />vision<br />- Difficulty thinking, remembering information, or<br />solving problems, being less alert or aware, feeling<br />very sleepy with low energy &ndash; these symptoms may<br />be a sign of a high level of ammonia in the blood<br />(hyperammonemia), which can lead to a change in<br />brain function (hyperammonemic encephalopathy).<br />Other side effects include the following, if they get<br />serious, please tell your doctor or pharmacist:<br />Very common (may affect more than 1 in 10<br />people)<br />- Stuffy, runny nose or sore throat</p><p>- Tingling, pain and/or numbness of various body<br />parts - Sleepiness, tiredness - Dizziness<br />- Nausea, diarrhoea - Weight loss<br />Common (may affect up to 1 in 10 people)<br />- Anaemia (low blood count)<br />- Allergic reaction (such as skin rash, redness, itching,<br />facial swelling, hives)<br />- Loss of appetite, decreased appetite<br />- Aggression, agitation, anger, abnormal behaviour<br />- Difficulty falling or staying asleep<br />- Problems with speech or speech disorder, slurred<br />speech<br />- Clumsiness or lack of coordination, feeling of<br />unsteadiness when walking<br />- Decreased ability to complete routine tasks<br />- Decreased, loss of, or no sense of taste<br />- Involuntary trembling or shaking; rapid,<br />uncontrollable movements of the eyes<br />- Visual disturbance, such as double vision, blurred<br />vision, decreased vision, difficulty focusing<br />- Sensation of spinning (vertigo), ringing in the ears,<br />ear pain<br />- Shortness of breath - Cough - Nose bleeds - Fever,<br />not feeling well, weakness<br />- Vomiting, constipation, abdominal pain or<br />discomfort, indigestion, stomach or intestinal<br />infection - Dry mouth - Hair loss - Itching<br />- Joint pain or swelling, muscle spasms or twitching,<br />muscle aches or weakness, chest pain<br />- Weight gain<br />Uncommon (may affect up to 1 in 100 people)<br />- Decrease in platelets (blood cells that help stop<br />bleeding), decrease in white blood cells that help to<br />protect you against infection, decrease in potassium<br />level in the blood<br />- Increase in liver enzymes, increase in eosinophils (a<br />type of white blood cell) in the blood<br />- Swollen glands in the neck, armpit, or groin<br />- Increased appetite<br />- Elevated mood<br />- Hearing, seeing, or feeling things that are not there,<br />severe mental disorder (psychosis)<br />- Showing and/or feeling no emotion, unusual<br />suspiciousness, panic attack<br />- Problems with reading, speech disorder, problems<br />with handwriting<br />- Restlessness, hyperactivity<br />- Slowed thinking, decreased wakefulness or alertness<br />- Reduced or slow body movements, involuntary<br />abnormal or repetitive muscle movements<br />- Fainting<br />- Abnormal sense of touch; impaired sense of touch<br />- Impaired, distorted, or no sense of smell<br />- Unusual feeling or sensation that may precede a<br />migraine or a certain type of seizure<br />- Dry eye, sensitivity of the eyes to light, eyelid<br />twitching, watery eyes<br />- Decreased or loss of hearing, loss of hearing in one<br />ear<br />- Slow or irregular heartbeat, feeling your heart<br />beating in your chest<br />- Low blood pressure, low blood pressure upon<br />standing (consequently, some people taking Alevio&trade;<br />may feel faint, dizzy, or may pass out when they<br />stand up or sit up suddenly)<br />- Flushing, feeling warm<br />- Pancreatitis (inflammation of the pancreas)<br />- Excessive passing of gas or wind, heartburn,<br />abdominal fullness or bloating<br />- Bleeding gums, increased saliva, drooling, breath<br />odour<br />- Excessive intake of fluids, thirst<br />- Skin discolouration<br />- Muscle stiffness, pain in side<br />- Blood in urine, incontinence (lack of control) of<br />urine, urgent desire to urinate, flank or kidney pain<br />- Difficulty getting or keeping an erection, sexual<br />dysfunction<br />- Flu-like symptoms<br />- Cold fingers and toes<br />- Feeling drunk<br />- Learning disability<br />Rare (may affect up to 1 in 1,000 people)<br />- Abnormally elevated mood<br />- Loss of consciousness<br />- Blindness in one eye, temporary blindness, night<br />blindness<br />- Lazy eye<br />- Swelling in and around the eyes<br />- Numbness, tingling and colour change (white, blue<br />then red) in fingers and toes when exposed to the cold<br />- Inflammation of the liver, liver failure<br />- Stevens Johnson syndrome, a potentially<br />life-threatening condition that may present with sores<br />in multiple mucosal sites (such as the mouth, nose,<br />and eyes), a skin rash, and blistering<br />- Abnormal skin odour<br />- Discomfort in your arms or legs<br />- Kidney disorder<br />Not known (frequency cannot be estimated from<br />the available data)<br />- Maculopathy is a disease of the macula, the small<br />spot in the retina where vision is keenest. You should<br />call your doctor if you notice a change or decrease in<br />your vision.<br />- Toxic epidermal necrosis, a life-threatening<br />condition related to, yet more severe than,<br />Stevens-Johnson syndrome, characterized by<br />widespread blistering and sloughing of the outer<br />layers of the skin (see rare side effects)<br />Children<br />The side effects in children are generally similar to<br />those seen in adults, but the following side effects<br />may be more common in children than adults:<br />- Problems with concentration<br />- Increased acid level in the blood<br />- Having thoughts of serious self-harm<br />- Tiredness<br />- Decreased or increased appetite<br />- Aggression, abnormal behaviour<br />- Difficulty falling or staying asleep<br />- Feeling of unsteadiness when walking<br />- Not feeling well<br />- Decrease in potassium level in the blood<br />- Showing and/or feeling no emotion<br />- Watery eyes<br />- Slow or irregular heartbeat<br />Other side effects that may occur in children are:<br />Common (may affect up to 1 in 10 people)<br />- Sensation of spinning (vertigo) - Vomiting - Fever<br />Uncommon (may affect up to 1 in 100 people)<br />- Increase in eosinophils (a type of white blood cell)<br />in the blood<br />- Hyperactivity - Feeling warm - Learning disability<br />Reporting of side effects<br />If you get any side effects, talk to your doctor or<br />pharmacist. This includes any possible side effects<br />not listed in this leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.<br />Do not use this medicine after the expiry date which<br />is stated on the carton after EXP.<br />Do not store above 30 &deg;C.<br />Advice to use within 2 months of bottle opening.<br />Do not throw away any medicines via wastewater or<br />household waste. Ask your pharmacist how to throw<br />away medicines you no longer use. These measures<br />will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Alevio&trade; contains<br />- The active substance is topiramate.<br />- Each Film Coated Tablet contains 25mg and 100mg<br />of Topiramate.<br />The other ingredients are:<br />Alevio&trade; 25mg:<br />Core: Lactose Monohydrate, Microcrystalline<br />Cellulose, Potato Starch Pregelatinized,<br />Sodium Starch Glycollate, Colloidal Silicon Dioxide<br />and Magnesium stearate.<br />Coating: Hydroxypropyl Methyl Cellulose, Titanium<br />dioxide, Polyethylene Glycol and Polysorbate 80.<br />Alevio&trade; 100mg:<br />Core: Lactose Monohydrate, Microcrystalline<br />Cellulose, Potato Starch Pregelatinized,<br />Sodium Starch Glycollate, Colloidal Silicon Dioxide<br />and Magnesium stearate.<br />Coating: Hydroxypropyl Methyl Cellulose, Titanium<br />dioxide, Polyethylene Glycol, Polysorbate 80 and<br />Iron Oxide Yellow.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Alevio™ 25mg: White to off white, round, biconvex,
film coated tablets, debossed with 'JP AA' one side
and plain on other side.
Alevio™ 100mg: Yellow coloured, round, biconvex,
film coated tablets, debossed with 'JP 146' one side
and plain on other side.
Alevio™ 25mg : 60 tablets packed in HDPE bottle.
Alevio™ 100mg: 60 tablets packed in HDPE bottle.
Not all packs may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Jamjoom Pharmaceuticals Factory Co.,<br />Jeddah, Saudi Arabia.<br />Tel: +966-12-6081111,<br />Fax: +966-12-6081222.<br />Website: www.jamjoompharma.com<br />To report any side effect(s):<br />&bull; Saudi Arabia:<br />The National Pharmacovigilance and Drug Safety<br />Centre (NPC)<br />o Fax: +966-11-205-7662<br />o Call NPC at +966-11-2038222,<br />Ext: 2317-2356-2340.<br />o Reporting hotline: 19999<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: www.sfda.gov.sa/npc<br />&bull; Other GCC States:<br />&minus; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                12-2024
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>ينتمي أليفيو&nbsp;إلى مجموعة من الأدوية تسمى &quot;مضادات الصرع`&nbsp;يُستخدَّم الدواء في الحالات التالية:</p><p>- لعلاج نوبات تشنج التي تصيب البالغين والأطفال الذين تزيد<br />أعمارهم عن ٦ أعوام عند استخدامه بمفرده.<br />- لعلاج نوبات تنشج التي تصيب البالغين والأطفال الذين يبلغ<br />عمرهم عامين أو أكثر عند استخدامه بمصاحبة أدوية أخرى.<br />- للوقاية من الصداع النصفي الذي يصيب البالغين.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تتناول أليفيو&nbsp;في الحالات التالية:</p><p>- إذا كنت تعاني من حساسية مفرطة تجاه توبيرامات أو أي مكون<br />من المكونات الأخرى الداخلة في تركيب هذا الدواء (المدرجة في<br />.( القسم رقم ٦<br />- إذا كنتِ حاملًا أو إذا كنت سيدة قادرة على الحمل عند استخدامه<br />للوقاية من الصداع النصفي، إلا إذا كنتِ تستخدمين وسائل منع حمل<br />فعالة (انظري قسم &quot;الحمل والرضاعة الطبيعية&quot; للتعرف على<br />المزيد من المعلومات). يتعين عليكِ استشارة الطبيب المعالج لكِ<br />بشأن أفضل وسائل لمنع الحمل يمكنكِ استخدامها خلال فترة تناول أليفيو.</p><p>تكن متأكدًا مما إذا كان أيٌّ مما سبق ينطبق عليك أم لا، استشر<br />الطبيب المعالج لك أو الصيدلي الخاص بك قبل تناول أليفيو.&nbsp;</p><p>تحذيرات واحتياطات<br />استشر الطبيب المعالج لك أو الصيدلي الخاص بك قبل تناوُل<br />في الحالات التَّالية: &trade; أليفيو<br />- إذا كنت تُعاني من مشكلات في الكلى، خاصة حصى الكلى أو<br />تخضع للغسيل الكلوي.<br />- إذا كنت تُعَاني من تاريخ مرضي من اضطرابات الدم وسوائل<br />الجسم (الحُماض الاستقلابي).<br />- إذا كنت تُعَاني من مشكلات في الكبد.<br />- إذا كنت تُعَاني من مشكلات في العينين، خاصة الزَّرَق.<br />- إذا كنت تُعَاني من مشكلة في النمو.<br />- إذا كنت تتبع نظام غذائي مرتفع الدهون (نظام غذائي كيتوني).<br />لعلاج الصرع بينما أنتِ حاملًا أو كنتِ &trade; - إذا كنتِ تتناولين أليفيو<br />سيدة قادرة على الإنجاب (انظري قسم &quot;الحمل والرضاعة الطبيعية&quot;<br />للتعرف على المزيد من المعلومات)<br />إذا لم تكن متأكدًا مما إذا كان أيٌّ مما سبق ينطبق عليك أم لا، فتحدَّث<br />.&trade; إلى الطبيب المعالج لك أو الصيدلي الخاص بك قبل تناول أليفيو<br />من المهم ألا تتوقف عن تناول الدواء الخاص بك دون استشارة<br />الطبيب المعالج لك أولًا.<br />كما يجب عليك أيضًاً استشارة الطبيب المعالج لك قبل تناول أي<br />.&trade; دواء يحتوي على توبيرامات الذي يُعطى إليك كبديل لأليفيو<br />لذا يجب متابعة ،&trade; قد تفقد بعض الوزن إذا كنت تستخدم أليفيو<br />وزنك دوريًّا خلال فترة تناول هذا الدواء. يجب عليك استشارة<br />الطبيب المعالج لك إذا كنت تفقد الكثير من الوزن أو إذا كان الطفل<br />الذي يتناول هذا الدواء لا يزيد وزنه بشكل كافٍ.<br />قد راود عدد قليل من الأشخاص الذين يُعالجون بأدوية مضادة<br />أفكار حول إيذاء أنفسهم أو الانتحار. اتصل ،&trade; للصرع، مثل أليفيو<br />بالطبيب المعالج لك فورًا إذا راودتك هذه الأفكار في أي وقت.<br />في حالات نادرة إلى ارتفاع مستويات الأمونيا في &trade; قد يؤدي أليفيو<br />الدم (تظهر في اختبارات الدم)، مما قد يسبب تغير في وظائف المخ،<br />خاصةً إذا كنت تتناول دواء يُسمي حمض فالبرويك أو فالبروات<br />الصوديوم. أخبر الطبيب المعالج لك على الفور إذا اصبت بأي من<br />الأعراض التالية، حيث إن هذه الحالة قد تكون خطيرة<br />(انظر أيضًا القسم رقم ٤ &quot;الآثار الجانبية المُحتمَلة&quot;):<br />- صعوبة في التفكير أو تذكر المعلومات أو حل المشكلات.<br />- انخفاض مستوى الانتباه أو الوعي.<br />- شعور بنعاس شديد مع انخفاض مستوى نشاط الجسم.<br />قد تزداد خطورة التعرض للإصابة بهذه الأعراض في حالة تناول<br />.&trade; جرعات مرتفعة من أليفيو<br />&trade; تناول أدوية أخرى مع أليفيو<br />أخبر الطبيب المعالج لك أو الصيدلي الخاص بك إذا كنت تستعمل<br />أية أدوية أخرى أو قد استعملتها مؤخرًا أو قد تستعملها فيما بعد. قد<br />على أدوية أخرى معينة أو يتأثر بها. يستلزم الأمر &trade; يؤثر أليفيو<br />.&trade; أحيانًا تعديل جرعة بعض الأدوية الأخرى الخاصة بك أو أليفيو<br />أخبر الطبيب المعالج لك أو الصيدلي الخاص بك على وجه<br />الخصوص إذا كنت تتناول أي من الأدوية التالية:<br />- أدوية أخرى تعيق مستوى تفكيرك أو تركيزك أو قدرتك على<br />التنسيق العضلي أو تقللها (مثل: مثبطات الجهاز العصبي المركزي،<br />مثل مرخيات العضلات والمهدئات).<br />من فعالية حبوب منع الحمل. &trade; - حبوب منع الحمل. قد يقلل أليفيو<br />يتعين عليكِ استشارة الطبيب المعالج لكِ بشأن أفضل وسائل منع<br />.&trade; الحمل التي يمكنكِ استخدامها خلال فترة تناول أليفيو<br />أخبري الطبيب المعالج لك إذا عانيتِ من اضطرابات الدورة<br />.&trade; الشهرية خلال فترة تناول حبوب منع الحمل و أليفيو<br />احتفظ بقائمة بجميع الأدوية التي تتناولها. اطلع الطبيب المعالج لك<br />أو الصيدلي الخاص بك على هذه القائمة قبل البدء في تناول أي<br />علاج جديد.<br />تتضمن الأدوية الأخرى التي يجب عليك مناقشة أمرها مع الطبيب<br />المعالج لك أو الصيدلي الخاص بك: أدوية مضادات الصرع،<br />ريسبيريدون، ليثيوم، هيدروكلوروثيازيد، ميتفورمين، بيوجليتازون،<br />جليبوريد، أميتريبتيلين، بروبرانولول، ديلتِيازِيم، فينلافاكسين،<br />فلونارازين، وعشبة سانت جونز (هايبريكوم برفوراتام)<br />(مستحضر عشبي يُستخدم في علاج الاكتئاب).<br />إذا لم تكن متأكدًا مما إذا كان أيٌّ مما سبق ينطبق عليك أم لا، فتحدَّث<br />.&trade; إلى الطبيب المعالج لك أو الصيدلي الخاص بك قبل تناول أليفيو<br />مع الطعام والمشروبات &trade; تناوُل أليفيو<br />مع الطعام أو بدونه. اشرب الكثير من السوائل &trade; يمكنك تناول أليفيو<br />طوال اليوم للوقاية من تكون حصى الكلى خلال فترة العلاج بأليفيو<br />يتعين عليك تجنب شرب الكحوليات خلال فترة العلاج .&trade;<br />&nbsp;بأليفيو.<br />الحمل والرضاعة الطبيعية<br />إذا كنت حاملاً أو ترضعين طبيعياً ، تعتقدين انك قد تكونين حامل أو<br />تخططين لإنجاب طفل ، فاطلبي من طبيبك النصيحة قبل تناول هذا<br />الدواء.<br />سوف يناقش طبيبك استخدام وسائل منع الحمل معك ، بالإضافة إلى<br />مناسب لك. كما هو الحال مع أدوية &trade; مناقشة ما إذا كانت أليفيو<br />مضادات الصرع الأخرى ، هناك خطر من الأذى للطفل الذي لم<br />أثناء الحمل. تأكدي من أنك تدركين &trade; يولد بعد إذا تم استخدام أليفيو<br />خلال &trade; جيدًا الفوائد المتوقعة والمخاطر المحتملة للعلاج بأليفيو<br />الحمل.<br />يجب أن لا تأخذي توباماكس للوقاية من الصداع النصفي إذا كنت<br />حاملاً أو قادرة على الحمل إلا إذا كنتِ تستخدمين وسائل منع حمل<br />فعالة.<br />أن &trade; يجب على الأمهات التي تُرضعن طبيعيًّا خلال تناول أليفيو<br />تخبر الطبيب المعالج لهن على الفور إذا عانى الطفل من أي شيء<br />غير معتاد.<br />القيادة واستخدام الآلات<br />قد تُصاب بأعراض مثل دوخة وتعب ومشكلات في الرؤية خلال<br />.&trade; فترة تلقي العلاج بأليفيو<br />يُحظر عليك قيادة السيارات أو استخدام أية أدوات أو آلات بدون<br />استشارة الطبيب المعالج لك أولاً.<br />على سكر اللاكتوز. &trade; يحتوي أليفيو<br />إذا أخبرك الطبيب المعالج لك بأنك لا تتحمل بعض أنواع<br />السكريات، فاستشره قبل تناوُل هذا المستحضر الدَّوائي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>تناول دائمًا هذا الدَّواء كما أخبرك الطبيب المعالج لك بالضبط. راجع<br />الطبيب المعالج لك أو الصيدلي الخاص بك إذا لم تكن متأكدًا من<br />كيفية التناول.<br />،&trade; - سوف يبدأ الطبيب المعالج لك عادة بجرعة منخفضة من أليفيو<br />ثم يزيد الجرعة ببطء حتى يصل إلى أفضل جرعة تلائم حالتك.<br />أقراص كاملًا. تجنب مضغ الأقراص إذ إنها قد &trade; - يجب بلع أليفيو<br />تكون ذات مذاق مر.<br />قبل الطعام أو خلاله أو بعده. اشرب الكثير &trade; - يمكن تناول أليفيو<br />من السوائل طوال اليوم للوقاية من تكون حصى الكلى خلال فترة<br />.&trade; العلاج بأليفيو<br />&trade; إذا تناولت كمية أكثر مما يجب من أليفيو<br />- توجه إلى الطبيب المعالج لك على الفور. اصطحب معك عبوة<br />الدواء.<br />- قد تشعر بالنعاس أو التعب أو قلة التنبه أو تواجه صعوبة في<br />التحدث أو التركيز أو تعاني من ازدواج الرؤية أو عدم وضوحها أو<br />تشعر بالدوخة نتيجة انخفاض ضغط الدم أو تشعر بالاكتئاب أو<br />الانفعال أو تعاني من ألم في البطن أو تصاب بنوبات (حالات)<br />تشنج.<br />قد يحدث فرط في تناول الجرعات إذا كنت تتلقى أدوية أخرى<br />.&trade; بمصاحبة أليفيو<br />&trade; إذا نسيت تناول أليفيو<br />إذا نسيت تناول إحدى الجرعات، فتناولها بمُجرد تذكُّرك لها. ومع<br />ذلك، إذا حان وقت تناوُل الجرعة التالية، فتجاوز الجرعة التي<br />نسيتها ثم استمر في تناول العلاج كالمعتاد. اتصل بالطبيب المعالج<br />لك إذا نسيت تناول جرعتين أو أكثر.<br />- يُحظر عليك تناول جرعة مضاعفة (جرعتين في نفس الوقت)<br />لتعويض الجرعة التي نسيتها.<br />&trade; إذا توقفت عن تناول أليفيو<br />يُحظر عليك وقف تناول هذا الدواء ما لم يخبرك الطبيب المعالج لك<br />بذلك. حيث قد تعود أعراض المرض في الظهور مرة أخرى في<br />حالة التوقف. إذا قرر الطبيب المعالج لك وقف هذا الدواء، فقد يقلل<br />جرعتك تدريجيًا على مدار بضعة أيام.<br />إذا كانت لديك أية أسئلة أخرى حول استخدام هذا المنتج، فاستشر<br />الطبيب المعالج لك أو الصيدلي الخاص بك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>قد يُسبب هذا الدواء آثارًا جانبية مثله مثل كافة الأدوية، على الرغم<br />من عدم حدوثها للجميع.<br />أخبر الطبيب المعالج لك على الفور أو احصل على رعاية طبية<br />فورًا، إذا أصبت بأي من الآثار الجانبية التالية:<br />أثار جانبية شائعة جدًّا (قد تُؤثر على أكثر من مريض واحد من بين<br />كل ۱۰ مرضى):<br />- اكتئاب (ظهر جديدًا أو أصبح أسوأ)<br />أثار جانبية شائعة (قد تُؤثر على ما يصل إلى مريض واحد من بين<br />كل ۱۰ مرضى):<br />- نوبات تشنجية (نوبات).<br />- قلق، هياج، اضطرابات مزاجية، ارتباك، توهان.<br />- مشكلات في التركيز، بطء التفكير، فقدان الذاكرة، مشكلات في<br />الذاكرة (ظهرت جديدًا أو تغيرت فجأة أو زادت شدتها).<br />- حصى بالكلى، زيادة عدد مرات التبول أو الشعور بألم عند التبول.<br />آثار جانبية غير شائعة (قد تؤثر على ما يصل إلى مريض واحد من<br />بين كل ۱۰۰ مريض):<br />- ارتفاع مستوى الأحماض في الدم (قد يؤدي إلى صعوبة التنفس<br />بما في ذلك ضيق النفس وفقدان الشهية وغثيان وقيء وتعب مفرط،<br />وتسارع ضربات القلب أو عدم انتظامها)<br />- انخفاض مستوى التعرق أو عدم التعرق (خاصة في الأطفال<br />الصغار الذين يتعرضون لدرجات حرارة مرتفعة).<br />- أفكار بإيذاء خطير للنفس أو محاولة إيذاء خطير للنفس.<br />- فقدان جزء من مجال الرؤية.<br />آثار جانبية نادرة (قد تُؤثر على ما يصل إلى مريض واحد من بين<br />كل ۱۰۰۰ مريض).<br />- زَرَق (جلوكوما)، انسداد السائل في العين مما يؤدي إلى ارتفاع<br />ضغط الدم في العين أو ألم أو قصور الرؤية.<br />- صعوبة في التفكير أو تذكر المعلومات أو حل المشكلات، انخفاض<br />مستوى الانتباه أو الوعي، الشعور بنعاس شديد مع انخفاض مستوى<br />نشاط الجسم- قد تدل هذه الأعراض على ارتفاع مستوى الأمونيا في<br />الدم (فرط الأمونيا في الدم)، والذي من شأنه أن يؤدي إلى تغيير<br />وظائف الدماغ (اعتلال الدماغ الناجم عن فرط الأمونيا في الدم).<br />يِرجى إبلاغ الطبيب المعالج لك أو الصيدلي الخاص بك، إذا<br />أصبحت أي من الآثار الجانبية الأخرى خطيرة وتضمنت ما يلي:<br />أثار جانبية شائعة جدًّا (قد تُؤثر على أكثر من مريض واحد من بين<br />كل ۱۰ مرضى):<br />- انسداد الأنف أو سيلانه أو التهاب الحلق.<br />- وخز و/أو ألم و/أو تنميل في أجزاء مختلفة من الجسم.<br />- نعاس، تعب.<br />- دوخة.<br />- غثيان، إسهال.<br />- فقدان الوزن.<br />أثار جانبية شائعة (قد تُؤثر على ما يصل إلى مريض واحد من بين<br />كل ۱۰ مرضى):<br />- فقر الدم (انخفاض عدد كريات الدم).<br />- تفاعلات حساسية (مثل طفح جلدي، احمرار الجلد، حكة، تورم<br />الوجه، أرتكاريا).<br />- فقدان الشهية، انخفاض الشهية.<br />- عدوانية، انفعال، غضب، سلوك غير طبيعي.<br />- صعوبة في النوم أو نوم متواصل.</p><p>- صعوبة في التحدث أو اضطراب الكلام أو تداخل الكلام.<br />- ارتباك أو عدم القدرة على التنسيق الحركي، شعور بعدم الثبات<br />عند المشي.<br />- انخفاض القدرة على إكمال الأعمال الروتينية.<br />- ضعف أو فقدان أو عدم الشعور بحاسة التذوق.<br />- ارتجاف أو ارتعاش لا إرادي، حركات سريعة لا إرادية في<br />العينين.<br />- اضطرابات الرؤية، مثل ازدواج الرؤية، عدم وضوح الرؤية،<br />قصور الرؤية، صعوبة في تركيز الرؤية.<br />- شعور بالدوران (دوار)، رنين في الأذنين، آلام في الأذنين.<br />- ضيق التنفس.<br />- سعال.<br />- نزيف الأنف.<br />- حمى، إعياء، ضعف.<br />- قيء، إمساك، ألم أو مغص بالبطن، عسر الهضم، عدوى في<br />المعدة أو الأمعاء.<br />- جفاف الفم.<br />- تساقط الشعر.<br />- حكة.<br />- آلام المفاصل أو تورمها، تقلصات عضلية أو انتفاض العضلات،<br />آلام العضلات أو ضعفها، ألم في الصدر.<br />- زيادة الوزن.<br />آثار جانبية غير شائعة (قد تؤثر على ما يصل إلى مريض واحد من<br />بين كل ۱۰۰ مريض):<br />- انخفاض عدد الصفائح الدموية (خلايا الدم التي تساعد على وقف<br />النزيف)، انخفاض عدد خلايا الدم البيضاء التي تساعد على محاربة<br />العدوى، انخفاض مستوى البوتاسيوم في الدم.<br />- ارتفاع مستوى إنزيمات الكبد، ارتفاع في مستوي الحمضات<br />(اليوزينات) (نوع من الخلايا البيضاء) في الدم.<br />- تورم الغدد في الرقبة أو الإبط أو الفخذ.<br />- زيادة الشهية.<br />- ارتفاع الحالة المزاجية.<br />- سماع أشياء غير موجودة أو رؤيتها أو الشعور بها، اضطرابات<br />عقلية حادة (ذهان).<br />- إظهار تبلد الإحساس و/أو عدم الإحساس، ارتياب غير طبيعي،<br />نوبات هلع.<br />- صعوبة في القراءة، اضطراب في الكلام، مشاكل في الكتابة باليد.<br />- عدم الراحة، فرط النشاط.<br />- بطء التفكير، انخفاض درجة التيقظ أو الانتباه.<br />- انخفاض معدل حركات الجسم أو بطء حركته، حركات عضلية<br />لاإرادية غير طبيعية أو متكررة.<br />- إغماء.<br />- اضطراب حاسة اللمس، ضعف حاسة اللمس.<br />- ضعف حاسة الشم أو تدهورها أو فقدانها.<br />- شعور أو احساس غير طبيعي قد يسبق الصداع النصفي أو نوع<br />معين من نوبات التشنج.<br />- جفاف العين، حساسية العينين تجاه الضوء، ارتعاش جفون<br />العينين، إفراز الدموع في العينين.<br />- ضعف حاسة السمع أو فقدان حاسة السمع أو فقدان السمع في أذن<br />واحدة.<br />- بطء ضربات القلب أو عدم انتظامها، شعور بشدة ضربات القلب<br />في الصدر.<br />- انخفاض ضغط الدم، انخفاض ضغط الدم عند الوقوف (وبالتالي،<br />بفقدان الوعي أو &trade; قد يشعر بعض الأشخاص الذين يتناولون أليفيو<br />الدوار، أو قد يتعرضون للإغماء عند الوقوف أو الجلوس فجأة).<br />- احمرار الجلد، شعور بالسخونة.<br />- التهاب البنكرياس (حالات التهاب البنكرياس).<br />- إخراج كمية كبيرة من الغازات أو الريح أو الحموضة أو امتلاء<br />البطن أو انتفاخها.<br />- نزيف اللثة زيادة إفراز اللعاب سيلان اللعاب، رائحة نفس كريهة<br />- الإفراط في تناول السوائل، عطش.<br />- تغير لون الجلد.<br />- تصلُّب العضلات، ألم في الجانب.<br />- وجود دم في البول، سلس البول (عدم القدرة على التحكم في<br />البول)، رغبة ملحة في التبول، ألم في الخاصرة أو الكلى.<br />- صعوبة الانتصاب أو الحفاظ على الانتصاب، ضعف القدرة<br />الجنسية.<br />- أعراض تشبه أعراض الأنفلونزا.</p><p>- برودة أصابع اليدين والقدمين.<br />- شعور بحالة ثمالة.<br />- صعوبة في التعلم.<br />آثار جانبية نادرة (قد تُؤثر على ما يصل إلى مريض واحد من بين<br />كل ۱۰۰۰ مريض).<br />- ارتفاع الحالة المزاجية بشكل غير طبيعي.<br />- فقدان الوعي.<br />- فقدان البصر في عين واحدة، عمى مؤقت، عمى ليلي.<br />- عين كسولة.<br />- تورم بالعينين وحولهما.<br />- تنميل ووخز في أصابع اليدين والقدمين وتغير لونهم (أبيض ثم<br />أزرق ثم أحمر) عند التعرض للبرودة.<br />- التهاب الكبد، فشل في وظائف الكبد.<br />- متلازمة ستيفنز جونسون هي حالة يحتمل أن تشكل خطورة على<br />الحياة، قد يصاب بها المريض مع الإصابة بتقرحات في عدة<br />مواضع مخاطية (مثل الفم والأنف والعينين)، طفح جلدي، ظهور<br />بثور.<br />- رائحة جلد غير طبيعية.<br />- شعور بعدم الراحة في الذراعين والساقين.<br />- اضطرابات الكلى.<br />آثار جانبية غير معروفة (لا يمكن تقدير معدل تكرارها من واقع<br />البيانات المتاحة)<br />- اضرابات ببُقْعَةُ القَرْنِيَّة وهو مرض يصيب بقعة الشبكية، وهي<br />بقعة تقع داخل الشبكية حيث تتركز الرؤية. يجب أن تخبر الطبيب<br />المعالج لك إذا لاحظت اضطراب أو قصور في الرؤية.<br />- نخر البشرة السُمي وهي حالة تشكل خطورة على الحياة تتعلق<br />بمتلازمة ستيفنز جونسون ولكنها أشد منها، وتتميز بانتشار البثور<br />في الجسم وتقشر طبقات الجلد الخارجية (انظر الآثار الجانبية<br />النادرة).<br />الأطفال<br />تتشابه الآثار الجانبية التي لوحظت في الأطفال عامة مع تلك الآثار<br />لدى البالغين، لكن قد تكون الآثار الجانبية التالية أكثر شيوعًا بين<br />الأطفال عن البالغين:<br />- مشكلات في التركيز.<br />- ارتفاع مستوى الأحماض في الدم.<br />- التفكير في إيذاء النفس بدرجة خطيرة.<br />- تعب.<br />- انخفاض الشهية أو زيادتها.<br />- عدوانية، سلوك غير طبيعي.<br />- صعوبة في النوم أو نوم متواصل.<br />- شعور بعدم الثبات عند المشي.<br />- شعور بالإعياء.<br />- انخفاض مستوى البوتاسيوم في الدم.<br />- إظهار تبلد الإحساس و/أو عدم الإحساس.<br />- إفراز الدموع.<br />- بطء ضربات القلب أو عدم انتظامها.<br />تتضمن الآثار الجانبية الأخرى التي قد تصيب الأطفال:<br />أثار جانبية شائعة (قد تُؤثر على ما يصل إلى مريض واحد من بين<br />كل ۱۰ مرضى):<br />- شعور بدوار (دوار).<br />- قيء.<br />- حمى.<br />آثار جانبية غير شائعة (قد تؤثر على ما يصل إلى مريض واحد من<br />بين كل ۱۰۰ مريض):<br />- ارتفاع عدد خلايا اليوزينيات (نوع من خلايا الدم البيضاء) في<br />الدم.<br />- فرط النشاط.<br />- شعور بالسخونة.<br />- صعوبة في التعلم.<br />الإبلاغ عن الآثار الجانبية<br />إذا أصبت بأي آثار جانبية، فتحدَّث إلى الطبيب المعالج لك أو<br />الصيدلي الخاص بك. ويشمل ذلك أية آثار جانبية مُحتمَلة، غير<br />المُدرجة في هذه النَّشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يُحفظ بعيدًا عن متناول و مرأى الأطفال.<br />لا تَستخدِم هذا الدواء بعد مدة انتهاء تاريخ الصلاحية المُدوَّن على<br />.&quot;EXP&quot; العبوة بعد كلمة<br />يحفظ في درجة حرارة لا تزيد عن ۳۰ درجة مئوية.<br />لا تتخلص من الأدوية عن طريق إلقائها في مياه الصرف أو مع<br />المخلفات المنزلية. استشر الصيدلي الخاص بك حول كيفية التَّخلص<br />من الأدوية التي لم تعد تستخدمها. تُساعد هذه الإجراءات في الحفاظ<br />على البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>على ماذا یحتوي ألیفیو<br />المادة الفعالة ھي توبیرامات.<br />- یحتوي كل قرص مغلف على ۲٥ ملجم و ۱۰۰ ملجم من<br />توبیرامات. تشمل المكونات الأخرى ما یلي:<br />۲٥ ملجم: &trade; ألیفیو<br />المحتوى الداخلي: لاكتوز أحادي الھیدرات، سیلیلوز دقیق التبلور،<br />نشا بطاطس مسبق التجلتن، جلیكولات نشا الصودیوم، ثاني أكسید<br />السیلیكون الغروي وستیرات الماغنسیوم.<br />الغلاف الخارجي: ھیدروكسي بروبیل میثیل السلیلوز، ثاني أكسید<br />. التیتانیوم، بولي إیثیلین الجلایكول وبولي سوربات ۸۰<br />۱۰۰ ملجم: &trade; ألیفیو<br />المحتوى الداخلي: لاكتوز أحادي الھیدرات، سیلیلوز دقیق التبلور،<br />نشا بطاطس مسبق التجلتن، جلیكولات نشا الصودیوم، ثاني أكسید<br />السیلیكون الغروي وستیرات الماغنسیوم.<br />الغلاف الخارجي: ھیدروكسي بروبیل میثیل السلیلوز، ثاني أكسید<br />التیتانیوم، بولي إیثیلین الجلایكول، بولي سوربات ۸۰ وأكسید<br />الحدید الأصفر</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:right">مستدیرة الشكل، محدبة الوجھین، محفور على أحد جانبھا<br />والجانب الآخر أملس. &quot;JP AA&quot;<br />۱۰۰ ملجم: أقراص مغلفة لونھا أصفر، مستدیرة الشكل، &trade; ألیفیو<br />والجانب &quot;JP محدبة الوجھین، محفور على أحد جانبھا &quot; 146<br />الآخر أملس.<br />۲٥ ملجم: ٦۰ قرص معبأة في عبوة من البولي ایثیلین &trade; ألیفیو<br />عالي الكثافة.<br />۱۰۰ ملجم: ٦۰ قرص معبأة في عبوة من البولي ایثیلین &trade; ألیفیو<br />عالي الكثافة.<br />قد لا تكون كل العبوات مطروحة بالسوق.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>شركة مصنع جمجوم للأدویة، جدة، المملكة العربیة السعودیة.<br />+۹٦٦-۱۲- ۹٦٦ + فاكس: ٦۰۸۱۲۲۲ -۱۲- ھاتف: ٦۰۸۱۱۱۱<br />www.jamjoompharma.com : الموقع الإلكتروني<br />للإبلاغ عن أي أثار جانبیھ:<br />&bull; المملكة العربیة السعودیة:<br />- المركز الوطني للتیقظ و السلامة الدوائیة<br />+۹٦٦-۱۱-۲۰٥- فاكس: ۷٦٦۲ o<br />للإتصال بالإدارة التنفیذیة للتیقظ وإدارة الأزمات. o<br />+۹٦٦-۱۱- ھاتف: ۲۰۳۸۲۲۲ o<br />۲۳٤۰-۲۳٥٦- تحویلة: ۲۳۱۷<br />الخط الساخن للإبلاغ: ۱۹۹۹۹ o<br />npc.drug@sfda.gov.sa : برید إلكتروني o<br />www.sfda.gov.sa/npc : الموقع الالكتروني o<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            12-2024
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Alevio 25 mg Film Coated Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each Tablet contains
25 mg of Topiramate
30 mg of Lactose Monohydrate
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film coated Tablets
White to off white colored, round biconvex, film coated tablets, debossed with "JP AA" on one side
and plain on other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Monotherapy in adults, adolescents and children over 6 years of age with partial seizures with or<br />without secondary generalised seizures, and primary generalised tonic-clonic seizures.<br />Adjunctive therapy in children aged 2 years and above, adolescents and adults with partial onset<br />seizures with or without secondary generalization or primary generalized tonic-clonic seizures and for<br />the treatment of seizures associated with Lennox-Gastaut syndrome.<br />Topiramate is indicated in adults for the prophylaxis of migraine headache after careful evaluation of<br />possible alternative treatment options. Topiramate is not intended for acute treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology<br />It is recommended that therapy be initiated at a low dose followed by titration to an effective dose.<br />Dose and titration rate should be guided by clinical response.<br />It is not necessary to monitor topiramate plasma concentrations to optimize therapy with Alevio. On<br />rare occasions, the addition of topiramate to phenytoin may require an adjustment of the dose of<br />phenytoin to achieve optimal clinical outcome. Addition or withdrawal of phenytoin and<br />carbamazepine to adjunctive therapy with Alevio may require adjustment of the dose of Alevio.<br />In patients with or without a history of seizures or epilepsy, antiepileptic drugs (AEDs) including<br />topiramate should be gradually withdrawn to minimize the potential for seizures or increased seizure<br />frequency. In clinical trials, daily dosages were decreased in weekly intervals by 50-100 mg in adults<br />with epilepsy and by 25-50 mg in adults receiving topiramate at doses up to 100 mg/day for migraine<br />prophylaxis. In paediatric clinical trials, topiramate was gradually withdrawn over a 2-8 week period.<br />Monotherapy epilepsy:<br />General<br />When concomitant AEDs are withdrawn to achieve monotherapy with topiramate, consideration<br />should be given to the effects this may have on seizure control. Unless safety concerns require an<br />abrupt withdrawal of the concomitant AED, a gradual discontinuation at the rate of approximately<br />one-third of the concomitant AED dose every 2 weeks is recommended.<br />When enzyme inducing medicinal products are withdrawn, topiramate levels will increase. A decrease<br />in Alevio (topiramate) dosage may be required if clinically indicated.<br />Adults<br />Dose and titration should be guided by clinical response. Titration should begin at 25 mg nightly for 1<br />week. The dosage should then be increased at 1- or 2-week intervals by increments of 25 or 50<br />mg/day, administered in two divided doses. If the patient is unable to tolerate the titration regimen,<br />smaller increments or longer intervals between increments can be used.<br />The recommended initial target dose for topiramate monotherapy in adults is 100 mg/day to 200<br />mg/day in 2 divided doses. The maximum recommended daily dose is 500 mg/day in 2 divided doses.</p><p>Some patients with refractory forms of epilepsy have tolerated topiramate monotherapy at doses of<br />1,000 mg/day. These dosing recommendations apply to all adults including the elderly in the absence<br />of underlying renal disease.<br />Paediatric population (children over 6 years of age)<br />Dose and titration rate in children should be guided by clinical outcome. Treatment of children over 6<br />years of age should begin at 0.5 to 1 mg/kg nightly for the first week. The dosage should then be<br />increased at 1 or 2 week intervals by increments of 0.5 to 1 mg/kg/day, administered in two divided<br />doses. If the child is unable to tolerate the titration regimen, smaller increments or longer intervals<br />between dose increments can be used.<br />The recommended initial target dose range for topiramate monotherapy in children over 6 years of<br />age is 100 mg/day depending on clinical response, (this is about 2.0mg/kg/day in children 6-16 years).<br />Adjunctive therapy epilepsy (partial onset seizures with or without secondary generalization, primary<br />generalized tonic-clonic seizures, or seizures associated with Lennox-Gastaut syndrome).<br />Adults<br />Therapy should begin at 25-50 mg nightly for one week. Use of lower initial doses has been reported,<br />but has not been studied systematically. Subsequently, at weekly or bi-weekly intervals, the dose<br />should be increased by 25-50 mg/day and taken in two divided doses. Some patients may achieve<br />efficacy with once-a-day dosing.<br />In clinical trials as adjunctive therapy, 200 mg was the lowest effective dose. The usual daily dose is<br />200-400 mg in two divided doses.<br />These dosing recommendations apply to all adults, including the elderly, in the absence of underlying<br />renal disease (see section 4.4).<br />Paediatric population (children aged 2 years and above)<br />The recommended total daily dose of Alevio (topiramate) as adjunctive therapy is approximately 5 to<br />9 mg/kg/day in two divided doses. Titration should begin at 25 mg (or less, based on a range of 1 to 3<br />mg/kg/day) nightly for the first week. The dosage should then be increased at 1- or 2-week intervals<br />by increments of 1 to 3 mg/kg/day (administered in two divided doses), to achieve optimal clinical<br />response.<br />Daily doses up to 30 mg/kg/day have been studied and were generally well tolerated.</p><p>Migraine<br />Adults<br />The recommended total daily dose of topiramate for prophylaxis of migraine headache is 100 mg/day<br />administered in two divided doses. Titration should begin at 25 mg nightly for 1 week. The dosage<br />should then be increased in increments of 25 mg/day administered at 1-week intervals. If the patient is<br />unable to tolerate the titration regimen, longer intervals between dose adjustments can be used.<br />Some patients may experience a benefit at a total daily dose of 50 mg/day. Patients have received a<br />total daily dose up to 200 mg/day. This dose may be benefit in some patients, nevertheless, caution is<br />advised due to an increase incidence of side effects.<br />Paediatric population<br />Alevio (topiramate) is not recommended for treatment or prevention of migraine in children due to<br />insufficient data on safety and efficacy.<br />General dosing recommendations for Alevio in special patient populations<br />Renal impairment<br />In patients with impaired renal function (CLCR &le; 70 mL/min) topiramate should be administered with<br />caution as the plasma and renal clearance of topiramate are decreased. Subjects with known renal<br />impairment may require a longer time to reach steady-state at each dose. Half of the usual starting and<br />maintenance dose is recommended (see section 5.2).<br />In patients with end-stage renal failure, since topiramate is removed from plasma by haemodialysis, a<br />supplemental dose of Alevio equal to approximately one-half the daily dose should be administered<br />on haemodialysis days. The supplemental dose should be administered in divided doses at the<br />beginning and completion of the haemodialysis procedure. The supplemental dose may differ based<br />on the characteristics of the dialysis equipment being used (see section 5.2).<br />Hepatic impairment<br />In patients with moderate to severe hepatic impairment topiramate should be administered with<br />caution as the clearance of topiramate is decreased.</p><p>Elderly<br />No dose adjustment is required in the elderly population providing renal function is intact.<br />Method of administration<br />Alevio is available in film-coated tablets and a hard capsule formulation, for oral administration. It is<br />recommended that film-coated tablets not be broken. The hard capsule formulation is provided for<br />those patients who cannot swallow tablets, e.g. paediatric and the elderly.<br />Alevio can be taken without regard to meals</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Migraine prophylaxis in pregnancy and in women of childbearing potential if not using a highly
effective method of contraception.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In situations where rapid withdrawal of topiramate is medically required, appropriate monitoring is<br />recommended (see section 4.2).<br />As with other AEDs, some patients may experience an increase in seizure frequency or the onset of<br />new types of seizures with topiramate. These phenomena may be the consequence of an overdose, a<br />decrease in plasma concentrations of concomitantly used AEDs, progress of the disease, or a<br />paradoxical effect.<br />Adequate hydration while using topiramate is very important. Hydration can reduce the risk of<br />nephrolithiasis (see below). Proper hydration prior to and during activities such as exercise or<br />exposure to warm temperatures may reduce the risk of heat-related adverse reactions (see section 4.8).</p><p>Women of childbearing potential<br />Topiramate may cause fetal harm and fetal growth restriction (small for gestational age and low birth<br />weight) when administered to a pregnant woman. The North American Antiepileptic Drug pregnancy<br />registry data for topiramate monotherapy showed an approximate 3 fold higher prevalence of major<br />congenital malformations (4.3%), compared with a reference group not taking AEDs (1.4%). In<br />addition, data from other studies indicate that, compared with monotherapy, there is an increased risk<br />of teratogenic effects associated with the use of AEDs in combination therapy.<br />Before the initiation of treatment with topiramate in a woman of childbearing potential, pregnancy<br />testing should be performed and a highly effective contraceptive method advised (see section 4.5).<br />The patient should be fully informed of the risks related to the use of topiramate during pregnancy<br />(see sections 4.3 and 4.6).<br />Oligohydrosis<br />Oligohydrosis (decreased sweating) has been reported in association with the use of topiramate.<br />Decreased sweating and hyperthermia (rise in body temperature) may occur especially in young<br />children exposed to high ambient temperature.<br />Mood disturbances/depression<br />An increased incidence of mood disturbances and depression has been observed during topiramate<br />treatment.<br />Suicide/suicide ideation<br />Suicidal ideation and behaviour have been reported in patients treated with anti-epileptic agents in<br />several indications. A meta-analysis of randomised placebo-controlled trials of AEDs has shown a<br />small increased risk of suicidal ideation and behaviour. The mechanism of this risk is not known and<br />the available data do not exclude the possibility of an increased risk for topiramate.<br />In double blind clinical trials, suicide related events (SREs) (suicidal ideation, suicide attempts and<br />suicide) occurred at a frequency of 0.5% in topiramate treated patients (46 out of 8,652 patients<br />treated) and at a nearly 3-fold higher incidence than those treated with placebo (0.2%; 8 out of 4,045<br />patients treated).</p><p>Patients therefore should be monitored for signs of suicidal ideation and behaviour and appropriate<br />treatment should be considered. Patients (and caregivers of patients) should be advised to seek<br />medical advice should signs of suicidal ideation or behaviour emerge.<br />Nephrolithiasis<br />Some patients, especially those with a predisposition to nephrolithiasis, may be at increased risk for<br />renal stone formation and associated signs and symptoms such as renal colic, renal pain or flank pain.<br />Risk factors for nephrolithiasis include prior stone formation, a family history of nephrolithiasis and<br />hypercalciuria. None of these risk factors can reliably predict stone formation during topiramate<br />treatment. In addition, patients taking other medicinal products associated with nephrolithiasis may be<br />at increased risk.<br />Decreased renal function<br />In patients with impaired renal function (CLCR &le; 70 mL/min) topiramate should be administered with<br />caution as the plasma and renal clearance of topiramate are decreased. For specific posology<br />recommendations in patients with decreased renal function, see section 4.2.<br />Decreased hepatic function<br />In hepatically-impaired patients, topiramate should be administered with caution as the clearance of<br />topiramate may be decreased.<br />Acute myopia and secondary angle closure glaucoma<br />A syndrome consisting of acute myopia associated with secondary angle closure glaucoma has been<br />reported in patients receiving topiramate. Symptoms include acute onset of decreased visual acuity<br />and/or ocular pain. Ophthalmologic findings can include myopia, anterior chamber shallowing, ocular<br />hyperaemia (redness) and increased intraocular pressure. Mydriasis may or may not be present. This<br />syndrome may be associated with supraciliary effusion resulting in anterior displacement of the lens<br />and iris, with secondary angle closure glaucoma. Symptoms typically occur within 1 month of<br />initiating topiramate therapy. In contrast to primary narrow angle glaucoma, which is rare under 40<br />years of age, secondary angle closure glaucoma associated with topiramate has been reported in<br />paediatric patients as well as adults. Treatment includes discontinuation of topiramate, as rapidly as&nbsp;possible in the judgment of the treating physician, and appropriate measures to reduce intraocular<br />pressure. These measures generally result in a decrease in intraocular pressure.<br />Elevated intraocular pressure of any aetiology, if left untreated, can lead to serious sequelae including<br />permanent vision loss.<br />A determination should be made whether patients with history of eye disorders should be treated with<br />topiramate.<br />Visual field defects<br />Visual field defects have been reported in patients receiving topiramate independent of elevated<br />intraocular pressure. In clinical trials, most of these events were reversible after topiramate<br />discontinuation. If visual field defects occur at any time during topiramate treatment, consideration<br />should be given to discontinuing the drug.<br />Metabolic acidosis<br />Hyperchloremic, non-anion gap, metabolic acidosis (i.e. decreased serum bicarbonate below the<br />normal reference range in the absence of respiratory alkalosis) is associated with topiramate<br />treatment. This decrease in serum bicarbonate is due to the inhibitory effect of topiramate on renal<br />carbonic anhydrase. Generally, the decrease in bicarbonate occurs early in treatment although it can<br />occur at any time during treatment. These decreases are usually mild to moderate (average decrease of<br />4 mmol/l at doses of 100 mg/day or above in adults and at approximately 6 mg/kg/day in paediatric<br />patients). Rarely, patients have experienced decreases to values below 10 mmol/l. Conditions or<br />therapies that predispose to acidosis (such as renal disease, severe respiratory disorders, status<br />epilepticus, diarrhoea, surgery, ketogenic diet, or certain medicinal products) may be additive to the<br />bicarbonate lowering effects of topiramate.</p><p>Chronic metabolic acidosis increases the risk of renal stone formation and may potentially lead to<br />osteopenia.<br />Chronic metabolic acidosis in paediatric patients can reduce growth rates. The effect of topiramate on<br />bone-related sequelae has not been systematically investigated in paediatric or adult populations.<br />Depending on underlying conditions, appropriate evaluation including serum bicarbonate levels is<br />recommended with topiramate therapy. If signs or symptoms are present (e.g. Kussmaul&#39;s deep&nbsp;breathing, dyspnoea, anorexia, nausea, vomiting, excessive tiredness, tachycardia or arrhythmia),<br />indicative of metabolic acidosis, measurement of serum bicarbonate is recommended. If metabolic<br />acidosis develops and persists, consideration should be given to reducing the dose or discontinuing<br />topiramate (using dose tapering).<br />Topiramate should be used with caution in patients with conditions or treatments that represent a risk<br />factor for the appearance of metabolic acidosis.<br />Impairment of cognitive function<br />Cognitive impairment in epilepsy is multifactorial and may be due to the underlying aetiology, due to<br />the epilepsy or due to the anti-epileptic treatment. There have been reports in the literature of<br />impairment of cognitive function in adults on topiramate therapy which required reduction in dosage<br />or discontinuation of treatment. However, studies regarding cognitive outcomes in children treated<br />with topiramate are insufficient and its effect in this regard still needs to be elucidated.<br />Hyperammonemia and encephalopathy<br />Hyperammonemia with or without encephalopathy has been reported with topiramate treatment (see<br />section 4.8). The risk for hyperammonemia with topiramate appears dose-related. Hyperammonemia<br />has been reported more frequently when topiramate is used concomitantly with valproic acid (see<br />section 4.5).<br />In patients who develop unexplained lethargy or changes in mental status associated with topiramate<br />monotherapy or adjunctive therapy, it is recommended to consider hyperammonemic encephalopathy<br />and measuring ammonia levels.<br />Nutritional supplementation<br />Some patients may experience weight loss whilst on treatment with topiramate. It is recommended<br />that patients on topiramate treatment should be monitored for weight loss. A dietary supplement or<br />increased food intake may be considered if the patient is losing weight while on topiramate.<br />Lactose intolerance<br />Alevio tablets contain lactose. Patients with rare hereditary problems of galactose intolerance, Lapp<br />lactase deficiency or glucose-galactose malabsorption should not take this medication.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Effects of Alevio on other antiepileptic medicinal products<br />The addition of Alevio to other AEDs (phenytoin, carbamazepine, valproic acid, phenobarbital,<br />primidone) has no effect on their steady-state plasma concentrations, except in the occasional patient,<br />where the addition of Alevio to phenytoin may result in an increase of plasma concentrations of<br />phenytoin. This is possibly due to inhibition of a specific enzyme polymorphic isoform (CYP2C19).<br />Consequently, any patient on phenytoin showing clinical signs or symptoms of toxicity should have<br />phenytoin levels monitored.<br />A pharmacokinetic interaction study of patients with epilepsy indicated the addition of topiramate to<br />lamotrigine had no effect on steady state plasma concentration of lamotrigine at topiramate doses of<br />100 to 400 mg/day. In addition, there was no change in steady state plasma concentration of<br />topiramate during or after removal of lamotrigine treatment (mean dose of 327 mg/day).<br />Topiramate inhibits the enzyme CYP 2C19 and may interfere with other substances metabolized via<br />this enzyme (e.g., diazepam, imipramin, moclobemide, proguanil, omeprazol).<br />Effects of other antiepileptic medicinal products on Alevio<br />Phenytoin and carbamazepine decrease the plasma concentration of topimarate. The addition or<br />withdrawal of phenytoin or carbamazepine to Alevio therapy may require an adjustment in dosage of<br />the latter. This should be done by titrating to clinical effect. The addition or withdrawal of valproic<br />acid does not produce clinically significant changes in plasma concentrations of Alevio and, therefore,<br />does not warrant dosage adjustment of Alevio. The results of these interactions are summarized<br />below:</p><p><img alt="" width="882" height="318" src="data:image/png;base64,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" /></p><p>&nbsp;Primidone &harr; NS<br />&harr; = No effect on plasma concentration (&le;15% change)<br />** = Plasma concentrations increase in individual patients<br />&darr; = Plasma concentrations decrease<br />NS = Not studied<br />AED = antiepileptic drug</p><p>Other medicinal product interactions<br />Digoxin<br />In a single-dose study, serum digoxin area under plasma concentration curve (AUC) decreased 12%<br />due to concomitant administration of Alevio. The clinical relevance of this observation has not been<br />established. When Alevio is added or withdrawn in patients on digoxin therapy, careful attention<br />should be given to the routine monitoring of serum digoxin.<br />Central nervous system depressants<br />Concomitant administration of Alevio and alcohol or other central nervous system (CNS) depressant<br />medicinal products has not been evaluated in clinical studies. It is recommended that Alevio not be<br />used concomitantly with alcohol or other CNS depressant medicinal products.<br />St John&#39;s Wort (Hypericum perforatum)<br />A risk of decreased plasma concentrations resulting in a loss of efficacy could be observed with coadministration<br />of topiramate and St John&#39;s Wort. There have been no clinical studies evaluating this<br />potential interaction.<br />Oral contraceptives<br />In a pharmacokinetic interaction study in healthy volunteers with a concomitantly administered<br />combination oral contraceptive product containing 1 mg norethindrone (NET) plus 35 &mu;g ethinyl<br />estradiol (EE), Alevio given in the absence of other medications at doses of 50 to 200 mg/day was not<br />associated with statistically significant changes in mean exposure (AUC) to either component of the<br />oral contraceptive. In another study, exposure to EE was statistically significantly decreased at doses&nbsp;of 200, 400, and 800 mg/day (18%, 21%, and 30%, respectively) when given as adjunctive therapy in<br />epilepsy patients taking valproic acid. In both studies, Alevio (50-200 mg/day in healthy volunteers<br />and 200-800 mg/day in epilepsy patients) did not significantly affect exposure to NET. Although<br />there was a dose dependent decrease in EE exposure for doses between 200-800 mg/day (in epilepsy<br />patients), there was no significant dose dependent change in EE exposure for doses of 50-200 mg/day<br />(in healthy volunteers). The clinical significance of the changes observed is not known. The<br />possibility of decreased contraceptive efficacy and increased breakthrough bleeding should be<br />considered in patients taking combination oral contraceptive products with Alevio. Patients taking<br />estrogen containing contraceptives should be asked to report any change in their bleeding patterns.<br />Contraceptive efficacy can be decreased even in the absence of breakthrough bleeding.<br />Lithium<br />In healthy volunteers, there was an observed reduction (18% for AUC) in systemic exposure for<br />lithium during concomitant administration with topiramate 200 mg/day. In patients with bipolar<br />disorder, the pharmacokinetics of lithium were unaffected during treatment with topiramate at doses<br />of 200 mg/day; however, there was an observed increase in systemic exposure (26% for AUC)<br />following topiramate doses of up to 600 mg/day. Lithium levels should be monitored when coadministered<br />with topiramate.<br />Risperidone<br />Drug-drug interaction studies conducted under single dose conditions in healthy volunteers and<br />multiple dose conditions in patients with bipolar disorder, yielded similar results. When administered<br />concomitantly with topiramate at escalating doses of 100, 250 and 400 mg/day there was a reduction<br />in risperidone (administered at doses ranging from 1 to 6 mg/day) systemic exposure (16% and 33%<br />for steady-state AUC at the 250 and 400 mg/day doses, respectively). However, differences in AUC<br />for the total active moiety between treatment with risperidone alone and combination treatment with<br />topiramate were not statistically significant. Minimal alterations in the pharmacokinetics of the total<br />active moiety (risperidone plus 9-hydroxyrisperidone) and no alterations for 9-hydroxyrisperidone<br />were observed. There were no significant changes in the systemic exposure of the risperidone total<br />active moiety or of topiramate. When topiramate was added to existing risperidone (1-6 mg/day)<br />treatment, adverse events were reported more frequently than prior to topiramate (250-400 mg/day)</p><p>introduction (90% and 54% respectively). The most frequently reported AE&#39;s when topiramate was<br />added to risperidone treatment were: somnolence (27% and 12%), paraesthesia (22% and 0%) and<br />nausea (18% and 9% respectively).<br />Hydrochlorothiazide (HCTZ)<br />A drug-drug interaction study conducted in healthy volunteers evaluated the steady-state<br />pharmacokinetics of HCTZ (25 mg every 24 h) and topiramate (96 mg every 12 h) when administered<br />alone and concomitantly. The results of this study indicate that topiramate Cmax increased by 27% and<br />AUC increased by 29% when HCTZ was added to topiramate. The clinical significance of this change<br />is unknown. The addition of HCTZ to topiramate therapy may require an adjustment of the topiramate<br />dose. The steady-state pharmacokinetics of HCTZ were not significantly influenced by the<br />concomitant administration of topiramate. Clinical laboratory results indicated decreases in serum<br />potassium after topiramate or HCTZ administration, which were greater when HCTZ and topiramate<br />were administered in combination.<br />Metformin<br />A drug-drug interaction study conducted in healthy volunteers evaluated the steady-state<br />pharmacokinetics of metformin and topiramate in plasma when metformin was given alone and when<br />metformin and topiramate were given simultaneously. The results of this study indicated that<br />metformin mean Cmax and mean AUC0-12h increased by 18% and 25%, respectively, while mean CL/F<br />decreased 20% when metformin was co-administered with topiramate. Topiramate did not affect<br />metformin tmax. The clinical significance of the effect of topiramate on metformin pharmacokinetics is<br />unclear. Oral plasma clearance of topiramate appears to be reduced when administered with<br />metformin. The extent of change in the clearance is unknown. The clinical significance of the effect<br />of metformin on topiramate pharmacokinetics is unclear.<br />When Alevio is added or withdrawn in patients on metformin therapy, careful attention should be<br />given to the routine monitoring for adequate control of their diabetic disease state.<br />Pioglitazone<br />A drug-drug interaction study conducted in healthy volunteers evaluated the steady-state<br />pharmacokinetics of topiramate and pioglitazone when administered alone and concomitantly. A 15%</p><p>decrease in the AUC ,ss of pioglitazone with no alteration in Cmax,ss was observed. This finding was<br />not statistically significant. In addition, a 13% and 16% decrease in Cmax,ss and AUC ,ss respectively,<br />of the active hydroxy-metabolite was noted as well as a 60% decrease in Cmax,ss and AUC ,ss of the<br />active keto-metabolite. The clinical significance of these findings is not known. When Alevio is<br />added to pioglitazone therapy or pioglitazone is added to Alevio therapy, careful attention should be<br />given to the routine monitoring of patients for adequate control of their diabetic disease state.<br />Glyburide<br />A drug-drug interaction study conducted in patients with type 2 diabetes evaluated the steady-state<br />pharmacokinetics of glyburide (5 mg/day) alone and concomitantly with topiramate (150 mg/day).<br />There was a 25% reduction in glyburide AUC24during topiramate administration. Systemic exposure<br />of the active metabolites, 4-trans-hydroxy-glyburide (M1) and 3-cis-hydroxyglyburide (M2), were<br />also reduced by 13% and 15%, respectively. The steady-state pharmacokinetics of topiramate were<br />unaffected by concomitant administration of glyburide.<br />When topiramate is added to glyburide therapy or glyburide is added to topiramate therapy, careful<br />attention should be given to the routine monitoring of patients for adequate control of their diabetic<br />disease state.<br />Other forms of interactions<br />Agents predisposing to nephrolithiasis<br />Alevio, when used concomitantly with other agents predisposing to nephrolithiasis, may increase the<br />risk of nephrolithiasis. While using Alevio, agents like these should be avoided since they may create<br />a physiological environment that increases the risk of renal stone formation.<br />Valproic acid<br />Concomitant administration of topiramate and valproic acid has been associated with<br />hyperammonemia with or without encephalopathy in patients who have tolerated either medicinal<br />product alone. In most cases, symptoms and signs abated with discontinuation of either medicinal<br />product (see section 4.4 and section 4.8). This adverse reaction is not due to a pharmacokinetic<br />interaction.</p><p>Hypothermia, defined as an unintentional drop in body core temperature to &lt;35&deg;C, has been reported<br />in association with concomitant use of topiramate and valproic acid (VPA) both in conjunction with<br />hyperammonemia and in the absence of hyperammonemia. This adverse event in patients using<br />concomitant topiramate and valproate can occur after starting topiramate treatment or after increasing<br />the daily dose of topiramate.<br />Additional pharmacokinetic drug interaction studies<br />Clinical studies have been conducted to assess the potential pharmacokinetic drug interaction between<br />topiramate and other agents. The changes in Cmax or AUC as a result of the interactions are<br />summarized below. The second column (concomitant drug concentration) describes what happens to<br />the concentration of the concomitant drug listed in the first column when topiramate is added. The<br />third column (topiramate concentration) describes how the coadministration of a drug listed in the<br />first column modifies the concentration of topiramate.</p><p><img alt="" width="637" height="453" src="data:image/png;base64,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" /></p><p><img alt="" width="691" height="299" src="data:image/png;base64,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" /></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy Category D<br />If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask<br />your doctor for advice before taking this medicine. Your doctor will discuss use of contraceptives<br />with you, as well as discussing whether Alevio&trade; is suitable for you. As with other anti-epileptic<br />medicines, there is a risk of harm to the unborn child if Alevio&trade; is used during pregnancy. Make sure<br />you are very clear about the risks and the benefits of using Alevio&trade; for epilepsy during pregnancy.<br />You should not take Alevio&trade; for migraine prevention if you are pregnant or you are able to become<br />pregnant and you are not using effective contraception. Mothers who breast-feed while taking<br />Alevio&trade; must tell the doctor as soon as possible if the baby experiences anything unusual.<br />Risk related to epilepsy and AEDs in general<br />Specialist advice should be given to women who are of childbearing potential. The need for treatment<br />with AEDs should be reviewed when a woman is planning to become pregnant. In women being<br />treated for epilepsy, sudden discontinuation of AED therapy should be avoided as this may lead to<br />breakthrough seizures that could have serious consequences for the woman and the unborn child.</p><p>Monotherapy should be preferred whenever possible because therapy with multiple AEDs could be<br />associated with a higher risk of congenital malformations than monotherapy, depending on the<br />associated antiepileptics.<br />Risk related to topiramate<br />Topiramate was teratogenic in mice, rats and rabbits (see section 5.3). In rats, topiramate crosses the<br />placental barrier.<br />In humans, topiramate crosses the placenta and similar concentrations have been reported in the<br />umbilical cord and maternal blood.<br />Clinical data from pregnancy registries indicate that infants exposed to topiramate monotherapy have:<br />&bull; An increased risk of congenital malformations (particularly cleft lip/palate, hypospadias, and<br />anomalies involving various body systems) following exposure during the first trimester. The North<br />American Antiepileptic Drug pregnancy registry data for topiramate monotherapy showed an<br />approximate 3-fold higher prevalence of major congenital malformations (4.3%), compared with a<br />reference group not taking AEDs (1.4%). In addition, data from other studies indicate that, compared<br />with monotherapy, there is an increased risk of teratogenic effects associated with the use of AEDs in<br />combination therapy. The risk has been reported to be dose dependent; effects were observed in all<br />doses. In women treated with topiramate who have had a child with a congenital malformation, there<br />appears to be an increased risk of malformations in subsequent pregnancies when exposed to<br />topiramate.<br />&bull; A higher prevalence of low birth weight (&lt;2500 grams) compared with a reference group.<br />&bull; An increased prevalence of being small for gestational age (SGA; defined as birth weight below the<br />10th percentile corrected for their gestational age, stratified by sex). The long term consequences of<br />the SGA findings could not be determined.<br />Indication epilepsy<br />It is recommended to consider alternative therapeutic options in women of child bearing potential. If<br />topirmate is used in women of childbearing potential, it is recommended that highly effective<br />contraception be used (see section 4.5), and that the woman is fully informed of the known risks of<br />uncontrolled epilepsy to the pregnancy and the potential risks of the medicinal product to the foetus.</p><p>If a woman plans a pregnancy, a preconceptional visit is recommended in order to reassess the<br />treatment, and to consider other therapeutic options. In case of administration during the first<br />trimester, careful prenatal monitoring should be performed.<br />Indication migraine prophylaxis<br />Topiramate is contraindicated in pregnancy and in women of childbearing potential if a highly<br />effective method of contraception is not used (see sections 4.3 and 4.5).<br />Brest-feeding<br />Animal studies have shown excretion of topiramate in milk. The excretion of topiramate in human<br />milk has not been evaluated in controlled studies. Limited observations in patients suggest an<br />extensive excretion of topiramate into breast milk. Effects that have been observed in breastfed<br />newborns/infants of treated mothers, include diarrhea, drowsiness, irritability and inadequate weight<br />gain. Therefore, a decision must be made whether to suspend breast-feeding or to discontinue/ abstain<br />from topiramate therapy taking into account the importance of the medicinal product to the mother<br />(see section 4.4).<br />Fertility<br />Animal studies did not reveal impairment of fertility by topiramate (see section 5.3). The effect of<br />topiramate on human fertility has not been established.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Alevio has minor or moderate influence on the ability to drive and use machines. Topiramate acts on<br />the central nervous system and may produce drowsiness, dizziness or other related symptoms. It may<br />also cause visual disturbances and/or blurred vision. These adverse reactions could potentially be<br />dangerous in patients driving a vehicle or operating machinery, particularly until such time as the<br />individual patient&#39;s experience with the medicinal products established.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The safety of topiramate was evaluated from a clinical trial database consisting of 4,111 patients<br />(3,182 on topiramate and 929 on placebo) who participated in 20 double-blind trials and 2,847<br />patients who participated in 34 open-label trials, respectively, for topiramate as adjunctive treatment<br />of primary generalized tonic-clonic seizures, partial onset seizures, seizures associated with Lennox-<br />Gastaut syndrome, monotherapy for newly or recently diagnosed epilepsy or migraine prophylaxis.<br />The majority of adverse reactions were mild to moderate in severity. Adverse reactions identified in<br />clinical trials, and during post-marketing experience (as indicated by &ldquo;*&rdquo;) are listed by their incidence<br />in clinical trials in Table 1. Assigned frequencies are as follows:<br />Very common &ge;1/10<br />Common &ge;1/100 to &lt;1/10<br />Uncommon &ge;1/1,000 to &lt;1/100<br />Rare &ge;1/10,000 to &lt;1/1,000<br />Not known cannot be estimated from the available data<br />The most common adverse reactions (those with an incidence of &gt;5% and greater than that observed<br />in placebo in at least 1 indication in double-blind controlled studies with topiramate) include:<br />anorexia, decreased appetite, bradyphrenia, depression, expressive language disorder, insomnia,<br />coordination abnormal, disturbance in attention, dizziness, dysarthria, dysgeusia, hypoesthesia,<br />lethargy, memory impairment, nystagmus, paresthesia, somnolence, tremor, diplopia, vision blurred,<br />diarrhoea, nausea, fatigue, irritability, and weight decreased.<br />&nbsp;</p><p>Infections and<br />infestations<br />Nasopharyngitis*<br />Blood and<br />lymphatic<br />system<br />Anaemia Leucopenia,<br />thrombocytopenia<br />lymphadenopathy,<br />Neutropenia</p><p>Immune system<br />disorders<br />Hypersensitivity Allergic<br />oedema*<br />Metabolism and<br />nutrition<br />disorders<br />Anorexia,<br />decreased<br />appetite<br />Metabolic<br />acidosis,<br />hypokalaemia,<br />increased<br />appetite,<br />polydipsia<br />Acidosis<br />hyperchloraemic,<br />hyperammonemia*,<br />hyperammonemic<br />encephalopathy*<br />Psychiatric<br />disorders<br />Depression Bradyphrenia,<br />insomnia,<br />expressive<br />language<br />disorder,<br />anxiety,<br />confusional<br />state,<br />disorientation,<br />aggression,<br />mood altered,<br />agitation, mood<br />swings,<br />depressed<br />mood, anger,<br />abnormal<br />behaviour<br />Suicidal ideation,<br />suicide attempt,<br />hallucination,<br />psychotic<br />disorder,<br />hallucination<br />auditory,<br />hallucination<br />visual, apathy,<br />lack of<br />spontaneous<br />speech, sleep<br />disorder, affect<br />lability, libido<br />decreased,<br />restlessness,<br />crying,<br />dysphemia,<br />euphoric mood,<br />paranoia,<br />perseveration,<br />Mania, panic<br />disorder, feeling of<br />despair*,<br />hypomania</p><p>panic attack,<br />tearfulness,<br />reading disorder,<br />initial insomnia,<br />flat affect,<br />thinking<br />abnormal, loss of<br />libido, listless,<br />middle insomnia,<br />distractibility,<br />early morning<br />awakening, panic<br />reaction, elevated<br />mood<br />Nervous system<br />disorders<br />Paraesthesia,<br />somnolence<br />Dizziness<br />Disturbance in<br />attention,<br />memory<br />impairment,<br />amnesia,<br />cognitive<br />disorder, mental<br />impairment,<br />psychomotor<br />skills impaired,<br />convulsion,<br />coordination<br />abnormal,<br />tremor,<br />lethargy,<br />hypoaesthesia,<br />Depressed level<br />of consciousness,<br />grand mal<br />convulsion, visual<br />field defect,<br />complex partial<br />seizures, speech<br />disorder,<br />psychomotor<br />hyperactivity,<br />syncope, sensory<br />disturbance,<br />drooling,<br />hypersomnia,<br />aphasia, repetitive<br />speech,<br />Apraxia, circadian<br />rhythm sleep<br />disorder,<br />hyperaesthesia,<br />hyposmia,<br />anosmia, essential<br />tremor, akinesia,<br />unresponsive to<br />stimuli</p><p>nystagmus,<br />dysgeusia,<br />balance<br />disorder,<br />dysarthria,<br />intention<br />tremor, sedation<br />hypokinesia,<br />dyskinesia,<br />dizziness postural,<br />poor quality sleep,<br />burning sensation,<br />sensory loss,<br />parosmia,<br />cerebellar<br />syndrome,<br />dysaesthesia,<br />hypogeusia,<br />stupor,<br />clumsiness, aura,<br />ageusia,<br />dysgraphia,<br />dysphasia,<br />neuropathy<br />peripheral,<br />presyncope,<br />dystonia,<br />formication<br />Eye disorders Vision blurred,<br />diplopia, visual<br />disturbance<br />Visual acuity<br />reduced, scotoma,<br />myopia*,<br />abnormal<br />sensation in eye*,<br />dry eye,<br />photophobia,<br />blepharospasm,<br />lacrimation<br />Blindness<br />unilateral,<br />blindness transient,<br />glaucoma,<br />accommodation<br />disorder, altered<br />visual depth<br />perception,<br />scintillating<br />Angle closure<br />glaucoma*,<br />Maculopathy*,<br />eye movement<br />disorder*,<br />conjunctival<br />oedema*</p><p>increased,<br />photopsia,<br />mydriasis,<br />presbyopia<br />scotoma, eyelid<br />oedema*, night<br />blindness,<br />amblyopia<br />Ear and<br />labyrinth<br />disorders<br />Vertigo,<br />tinnitus, ear<br />pain<br />Deafness,<br />deafness<br />unilateral,<br />deafness<br />neurosensory, ear<br />discomfort,<br />hearing impaired<br />Cardiac<br />disorders<br />Bradycardia,<br />sinus bradycardia,<br />palpitations<br />Vascular<br />disorders<br />Hypotension,<br />orthostatic<br />hypotension,<br />flushing, hot flush<br />Raynaud&#39;s<br />phenomenon<br />Respiratory,<br />thoracic and<br />mediastinal<br />disorders<br />Dyspnoea ,<br />epistaxis, nasal<br />congestion,<br />rhinorrhoea,<br />cough*<br />Dyspnoea<br />exertional,<br />Paranasal sinus<br />hypersecretion,<br />dysphonia<br />Gastrointestinal<br />disorders<br />Nausea,<br />diarrhoea<br />Vomiting,<br />constipation,<br />abdominal pain<br />upper,<br />dyspepsia,<br />abdominal pain,<br />Pancreatitis,<br />flatulence,<br />gastrooesophageal<br />reflux disease,<br />abdominal pain<br />lower,</p><p>dry mouth,<br />stomach<br />discomfort,<br />paraesthesia<br />oral, gastritis,<br />abdominal<br />discomfort<br />hypoaesthesia<br />oral, gingival<br />bleeding,<br />abdominal<br />distension,<br />epigastric<br />discomfort,<br />abdominal<br />tenderness,<br />salivary<br />hypersecretion,<br />oral pain, breath<br />odour,<br />glossodynia<br />Hepatobiliary<br />disorders<br />Hepatitis, Hepatic<br />failure<br />Skin and<br />subcutaneous<br />tissue disorders<br />Alopecia, rash,<br />pruritus<br />Anhidrosis,<br />hypoaesthesia<br />facial, urticaria,<br />erythema, pruritus<br />generalised, rash<br />macular, skin<br />discolouration,<br />dermatitis<br />allergic, swelling<br />face<br />Stevens-Johnson<br />syndrome*<br />erythema<br />multiforme*, skin<br />odour abnormal,<br />periorbital<br />oedema*, urticaria<br />localised<br />Toxic<br />epidermal<br />necrolysis*<br />Musculoskeletal<br />and connective<br />tissue disorders<br />Arthralgia,<br />muscle spasms,<br />myalgia, muscle<br />twitching,<br />Joint swelling*,<br />musculoskeletal<br />stiffness, flank<br />pain, muscle<br />Limb discomfort</p><p>muscular<br />weakness,<br />musculoskeletal<br />chest pain<br />fatigue<br />Renal and<br />urinary<br />disorders<br />Nephrolithiasis,<br />pollakiuria,<br />dysuria<br />Calculus urinary,<br />urinary<br />incontinence,<br />haematuria,<br />incontinence,<br />micturition<br />urgency, renal<br />colic, renal pain<br />Calculus ureteric,<br />renal tubular<br />acidosis*<br />Reproductive<br />system and<br />breast disorders<br />Erectile<br />dysfunction,<br />sexual<br />dysfunction<br />General<br />disorders and<br />administration<br />site conditions<br />Fatigue Pyrexia,<br />asthenia,<br />irritability, gait<br />disturbance,<br />feeling<br />abnormal,<br />malaise<br />Hyperthermia,<br />thirst, influenza<br />like illness*,<br />sluggishness,<br />peripheral<br />coldness, feeling<br />drunk, feeling<br />jittery<br />Face oedema,<br />calcinosis<br />Investigations Weight<br />decreased<br />Weight<br />increased*<br />Crystal urine<br />present, tandem<br />gait test abnormal,<br />white blood cell<br />count decreased,<br />Blood bicarbonate<br />decreased</p><p>Congenital malformations and fetal growth restrictions (see section 4.4 and section 4.6).<br />Paediatric population<br />Adverse reactions reported more frequently (&ge;2-fold) in children than in adults in double-blind<br />controlled studies include:<br />&bull; Decreased appetite<br />&bull; Increased appetite<br />&bull; Hyperchloraemic acidosis<br />&bull; Hypokalaemia<br />&bull; Abnormal behaviour<br />&bull; Aggression<br />&bull; Apathy<br />&bull; Initial insomnia<br />&bull; Suicidal ideation<br />&bull; Disturbance in attention<br />&bull; Lethargy<br />&bull; Circadian rhythm sleep disorder<br />&bull; Poor quality sleep</p><p>&bull; Lacrimation increased<br />&bull; Sinus bradycardia<br />&bull; Feeling abnormal<br />&bull; Gait disturbance.<br />Adverse reactions that were reported in children but not in adults in double-blind controlled studies<br />include:<br />&bull; Eosinophilia<br />&bull; Psychomotor hyperactivity<br />&bull; Vertigo<br />&bull; Vomiting<br />&bull; Hyperthermia<br />&bull; Pyrexia<br />&bull; Learning disability.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Signs and symptoms<br />Overdoses of topiramate have been reported. Signs and symptoms included convulsions, drowsiness,<br />speech disturbances, blurred vision, diplopia, impaired mentation, lethargy, abnormal coordination,<br />stupor, hypotension, abdominal pain, agitation, dizziness and depression. The clinical consequences<br />were not severe in most cases, but deaths have been reported after overdoses with multiple medicinal<br />products including topiramate.<br />Topiramate overdose can result in severe metabolic acidosis (see section 4.4).<br />Treatment<br />In acute topiramate overdose, if the ingestion is recent, the stomach should be emptied immediately<br />by lavage or by induction of emesis. Activated charcoal has been shown to adsorb topiramate in vitro.<br />Treatment should be appropriately supportive and the patient should be well hydrated. Haemodialysis<br />has been shown to be an effective means of removing topiramate from the body.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: antiepileptics, other antiepileptics, antimigraine preparations,<br />ATC code: N03AX11<br />Topiramate is classified as a sulfamate-substituted monosaccharide. The precise mechanism by which<br />topiramate exerts its antiseizure and migraine prophylaxis effects are unknown. Electrophysiological<br />and biochemical studies on cultured neurons have identified three properties that may contribute to<br />the antiepileptic efficacy of topiramate.<br />Action potentials elicited repetitively by a sustained depolarization of the neurons were blocked by<br />topiramate in a time-dependent manner, suggestive of a state-dependent sodium channel blocking<br />action. Topiramate increased the frequency at which &gamma;-aminobutyrate (GABA) activated GABAA<br />receptors, and enhanced the ability of GABA to induce a flux of chloride ions into neurons,<br />suggesting that topiramate potentiates the activity of this inhibitory neurotransmitter.</p><p>This effect was not blocked by flumazenil, a benzodiazepine antagonist, nor did topiramate increase<br />the duration of the channel open time, differentiating topiramate from barbiturates that modulate<br />GABAA receptors.<br />Because the antiepileptic profile of topiramate differs markedly from that of the benzodiazepines, it<br />may modulate a benzodiazepine-insensitive subtype of GABAA receptor. Topiramate antagonized the<br />ability of kainate to activate the kainate/AMPA (&alpha; -amino-3-hydroxy-5-methylisoxazole-4-propionic<br />acid) subtype of excitatory amino acid (glutamate) receptor, but had no apparent effect on the activity<br />of N-methyl-D-aspartate (NMDA) at the NMDA receptor subtype. These effects of topiramate were<br />concentration-dependent over a range of 1 &mu;M to 200 &mu;M, with minimum activity observed at 1 &mu;M<br />to 10 &mu;M.<br />In addition, topiramate inhibits some isoenzymes of carbonic anhydrase. This pharmacologic effect is<br />much weaker than that of acetazolamide, a known carbonic anhydrase inhibitor, and is not thought to<br />be a major component of topiramate&#39;s antiepileptic activity.<br />In animal studies, topiramate exhibits anticonvulsant activity in rat and mouse maximal electroshock<br />seizure (MES) tests and is effective in rodent models of epilepsy, which include tonic and absencelike<br />seizures in the spontaneous epileptic rat (SER) and tonic and clonic seizures induced in rats by<br />kindling of the amygdala or by global ischemia. Topiramate is only weakly effective in blocking<br />clonic seizures induced by the GABAA receptor antagonist, pentylenetetrazole.<br />Studies in mice receiving concomitant administration of topiramate and carbamazepine or<br />phenobarbital showed synergistic anticonvulsant activity, while combination with phenytoin showed<br />additive anticonvulsant activity. In well-controlled add-on trials, no correlation has been demonstrated<br />between trough plasma concentrations of topiramate and its clinical efficacy. No evidence of<br />tolerance has been demonstrated in man.<br />Absence seizures<br />Two small one arm studies were carried out with children aged 4-11 years old (CAPSS-326 and<br />TOPAMAT-ABS-001). One included 5 children and the other included 12 children before it was<br />terminated early due to lack of therapeutic response. The doses used in these studies were up to<br />approximately 12 mg/kg in study TOPAMAT-ABS-001 and a maximum of the lesser of 9 mg/kg/day<br />or 400 mg/day in study CAPSS-326. These studies do not provide sufficient evidence to reach<br />conclusion regarding efficacy or safety in the paediatric population.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The film-coated tablet and hard capsule formulations are bioequivalent.<br />The pharmacokinetic profile of topiramate compared to other AEDs shows a long plasma half-life,<br />linear pharmacokinetics, predominantly renal clearance, absence of significant protein binding, and<br />lack of clinically relevant active metabolites.<br />Topiramate is not a potent inducer of drug metabolizing enzymes, can be administered without regard<br />to meals, and routine monitoring of plasma topiramate concentrations is not necessary. In clinical<br />studies, there was no consistent relationship between plasma concentrations and efficacy or adverse<br />events.<br />Absorption<br />Topiramate is rapidly and well absorbed. Following oral administration of 100 mg topiramate to<br />healthy subjects, a mean peak plasma concentration (Cmax) of 1.5 &mu;g/ml was achieved within 2 to 3<br />hours (Tmax).<br />Based on the recovery of radioactivity from the urine the mean extent of absorption of a 100 mg oral<br />dose of 14C-topiramate was at least 81%. There was no clinically significant effect of food on the<br />bioavailability of topiramate.<br />Distribution<br />Generally, 13 to 17% of topiramate is bound to plasma protein. A low capacity binding site for<br />topiramate in/on erythrocytes that is saturable above plasma concentrations of 4 &mu;g/ml has been<br />observed. The volume of distribution varied inversely with the dose. The mean apparent volume of<br />distribution was 0.80 to 0.55 l/kg for a single dose range of 100 to 1200 mg. An effect of gender on<br />the volume of distribution was detected, with values for females circa 50% of those for males. This<br />was attributed to the higher percent body fat in female patients and is of no clinical consequence.<br />Biotransformation<br />Topiramate is not extensively metabolized (~20%) in healthy volunteers. It is metabolized up to 50%<br />in patients receiving concomitant antiepileptic therapy with known inducers of drug metabolizing<br />enzymes. Six metabolites, formed through hydroxylation, hydrolysis and glucuronidation, have been&nbsp;isolated, characterized and identified from plasma, urine and faeces of humans. Each metabolite<br />represents less than 3% of the total radioactivity excreted following administration of 14C-topiramate.<br />Two metabolites, which retained most of the structure of topiramate, were tested and found to have<br />little or no anticonvulsant activity.<br />Elimination<br />In humans, the major route of elimination of unchanged topiramate and its metabolites is via the<br />kidney (at least 81% of the dose). Approximately 66% of a dose of 14C-topiramate was excreted<br />unchanged in the urine within four days. Following twice a day dosing with 50 mg and 100 mg of<br />topiramate the mean renal clearance was approximately 18 ml/min and 17 ml/min, respectively. There<br />is evidence of renal tubular reabsorption of topiramate. This is supported by studies in rats where<br />topiramate was co-administered with probenecid, and a significant increase in renal clearance of<br />topiramate was observed. Overall, plasma clearance is approximately 20 to 30 ml/min in humans<br />following oral administration.<br />Linearity/non-linearity<br />Topiramate exhibits low intersubject variability in plasma concentrations and, therefore, has<br />predictable pharmacokinetics. The pharmacokinetics of topiramate are linear with plasma clearance<br />remaining constant and area under the plasma concentration curve increasing in a dose-proportional<br />manner over a 100 to 400 mg single oral dose range in healthy subjects. Patients with normal renal<br />function may take 4 to 8 days to reach steady-state plasma concentrations. The mean Cmax following<br />multiple, twice a day oral doses of 100 mg to healthy subjects was 6.76 &mu;g/ml. Following<br />administration of multiple doses of 50 mg and 100 mg of topiramate twice a day, the mean plasma<br />elimination half-life was approximately 21 hours.</p><p>Use with other AEDs<br />Concomitant multiple-dose administration of topiramate, 100 to 400 mg twice a day, with phenytoin<br />or carbamazepine shows dose proportional increases in plasma concentrations of topiramate.</p><p>Renal impairment<br />The plasma and renal clearance of topiramate are decreased in patients with moderate and severe<br />impaired renal function (CLCR &le; 70 ml/min). As a result, higher steady-state topiramate plasma<br />concentrations are expected for a given dose in renal-impaired patients as compared to those with<br />normal renal function. In addition, patients with renal impairment will require a longer time to reach<br />steady-state at each dose. In patients with moderate and severe renal impairment, half of the usual<br />starting and maintenance dose is recommended.<br />Topiramate is effectively removed from plasma by haemodialysis. A prolonged period of<br />hemodialysis may cause topiramate concentration to fall below levels that are required to maintain an<br />anti-seizure effect. To avoid rapid drops in topiramate plasma concentration during hemodialysis, a<br />supplemental dose of topiramate may be required. The actual adjustment should take into account 1)<br />the duration of dialysis period, 2) the clearance rate of the dialysis system being used, and 3) the<br />effective renal clearance of topiramate in the patient being dialyzed.<br />Hepatic impairment<br />Plasma clearance of topiramate decreased a mean of 26% in patients with moderate to severe hepatic<br />impairment. Therefore, topiramate should be administered with caution in patients with hepatic<br />impairment.<br />Elderly population<br />Plasma clearance of topiramate is unchanged in elderly subjects in the absence of underlying renal<br />disease.<br />Paediatric population (pharmacokinetics, up to 12 years of age)<br />The pharmacokinetics of topiramate in children, as in adults receiving add-on therapy, are linear, with<br />clearance independent of dose and steady-state plasma concentrations increasing in proportion to<br />dose. Children, however, have a higher clearance and a shorter elimination half-life. Consequently,<br />the plasma concentrations of topiramate for the same mg/kg dose may be lower in children compared<br />to adults. As in adults, hepatic enzyme inducing AEDs decrease the steady-state plasma<br />concentrations.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In nonclinical studies of fertility, despite maternal and paternal toxicity as low as 8 mg/kg/day, no<br />effects on fertility were observed, in male or female rats with doses up to 100 mg/kg/day.<br />In preclinical studies, topiramate has been shown to have teratogenic effects in the species studied<br />(mice, rats and rabbits). In mice, fetal weights and skeletal ossification were reduced at 500<br />mg/kg/day in conjunction with maternal toxicity. Overall numbers of fetal malformations in mice<br />were increased for all drug-treated groups (20, 100 and 500 mg/kg/day).<br />In rats, dosage-related maternal and embryo/fetal toxicity (reduced fetal weights and/or skeletal<br />ossification) were observed down to 20 mg/kg/day with teratogenic effects (limb and digit defects) at<br />400 mg/kg/day and above. In rabbits, dosage-related maternal toxicity was noted down to 10<br />mg/kg/day with embryo/fetal toxicity (increased lethality) down to 35 mg/kg/day, and teratogenic<br />effects (rib and vertebral malformations) at 120 mg/kg/day.<br />The teratogenic effects seen in rats and rabbits were similar to those seen with carbonic anhydrase<br />inhibitors, which have not been associated with malformations in humans. Effects on growth were<br />also indicated by lower weights at birth and during lactation for pups from female rats treated with 20<br />or 100 mg/kg/day during gestation and lactation. In rats, topiramate crosses the placental barrier.<br />In juvenile rats, daily oral administration of topiramate at doses up to 300 mg/kg/day during the<br />period of development corresponding to infancy, childhood, and adolescence resulted in toxicities<br />similar to those in adult animals (decreased food consumption with decreased body weight gain,<br />centrolobullar hepatocellular hypertrophy). There were no relevant effects on long bone (tibia) growth<br />or bone (femur) mineral density, preweaning and reproductive development, neurological<br />development (including assessments on memory and learning), mating and fertility or hysterotomy<br />parameters.<br />In a battery of in vitro and in vivo mutagenicity assays, topiramate did not show genotoxic potential.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lactose monohydrate<br />Microcrystalline Cellulose PH 101<br />Potato Starch Pregelatinized<br />Sodium Starch Glycolate<br />Colloidal Silicon Dioxide Aerosil 200<br />Magnesium Stearate<br />Opadry White 03B28796<br />Polysorbate 80<br />Purified Water</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pack sizes: 60&#39;s Bottles Pack</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused product should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                7. Marketing authorisation holder
Jamjoom Pharmaceuticals Factory Company
Plot No. ME1:3, Phase V, Industrial City, P.O. Box 6267, Jeddah-21442,
Kingdom of Saudi Arabia.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                12-2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>